Merlin is a negative regulator of human melanoma growth

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Murray, Lucas B ^a   Lau, Ying Ka Ingar ^a   Yu, Qin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; MERLIN; PROTEIN SERINE THREONINE KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; METASTATIC MELANOMA CELL; MOUSE; NONHUMAN;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROGEN PEROXIDE; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; NEOPLASM INVASIVENESS; NEUROFIBROMIN 2; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84865087898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043295     Document Type: Article

References (51)

1. Weatherhead SC, Haniffa M, Lawrence CM, (2007) Melanomas arising from naevi and de novo melanomas-does origin matter? Br J Dermatol 156: 72-76.
2. Hu S, Parmet Y, Allen G, Parker DF, Ma F, et al. (2009) Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch Dermatol 145: 1369-1374.
3. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, et al. (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745-2751.
4. Luikart SD, Kennealey GT, Kirkwood JM, (1984) Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 2: 164-168.
5. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM, (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16: 5-24.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
7. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000.
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
9. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
10. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, et al. (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363: 515-521.
11. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, et al. (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75: 826.
12. Evans DG, Huson SM, Donnai D, Neary W, Blair V, et al. (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84: 603-618.
13. Gutmann DH, Giordano MJ, Fishback AS, Guha A, (1997) Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 49: 267-270.
14. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI, (2003) NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17: 1090-1100.
15. Stamenkovic I, Yu Q, (2010) Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 11: 471-484.
16. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI, (2007) Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 177: 893-903.
17. Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, et al. (2003) Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23: 1493-1500.
18. Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH, (2009) The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol 29: 1472-1486.
19. Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, et al. (2009) Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 28: 854-865.
20. Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, et al. (2007) Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 26: 836-850.
21. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, et al. (2001) The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15: 968-980.
22. Xu Y, Stamenkovic I, Yu Q, (2010) CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 70: 2455-2464.
23. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, et al. (2003) Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 12: 841-849.
24. McCartney BM, Kulikauskas RM, LaJeunesse DR, Fehon RG, (2000) The neurofibromatosis-2 homologue, Merlin, and the tumor suppressor expanded function together in Drosophila to regulate cell proliferation and differentiation. Development 127: 1315-1324.
25. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, et al. (2008) Merlin is a potent inhibitor of glioma growth. Cancer Res 68: 5733-5742.
26. Zeng Q, Hong W, (2008) The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 13: 188-192.
27. Zhang N, Bai H, David KK, Dong J, Zheng Y, et al. (2010) The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19: 27-38.
28. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, et al. (2006) The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8: 27-36.
29. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, et al. (2009) Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64: 140-147.
30. Horiguchi A, Zheng R, Shen R, Nanus DM, (2008) Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate 68: 975-984.
31. Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, et al. (2011) Loss of Tumor Suppressor Merlin in Advanced Breast Cancer Is due to Post-translational Regulation. J Biol Chem 286: 40376-40385.
32. Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJ, et al. (1994) Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 6: 185-192.
33. Radu M, Chernoff J, (2009) The DeMSTification of mammalian Ste20 kinases. Curr Biol 19: R421-425.
34. Galcheva-Gargova Z, Zhidkova N, Geisler S, Ozug J, Wudyka S, et al. (2008) Overexpression of Merlin in B16F10 mouse melanoma cells reduces their metastatic activity: role of the cell surface heparan sulfate glycosaminoglycans. Int J Oncol 32: 1237-1243.
35. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, et al. (2009) YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 11: 1444-1450.
36. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, et al. (2010) Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 107: 1437-1442.
37. Song H, Mak KK, Topol L, Yun K, Hu J, et al. (2010) Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A 107: 1431-1436.
38. Zhou D, Conrad C, Xia F, Park JS, Payer B, et al. (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16: 425-438.
39. Xu ZP, Zhu JS, Zhang Q, Wang XY, (2011) A breakdown of the Hippo pathway in gastric cancer. Hepatogastroenterology 58: 1611-1617.
40. Zhou D, Zhang Y, Wu H, Barry E, Yin Y, et al. (2011) Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A 108: E1312-1320.
41. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, et al. (2005) The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24: 2076-2086.
42. Oka T, Mazack V, Sudol M, (2008) Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem 283: 27534-27546.
43. Zhao B, Wei X, Li W, Udan RS, Yang Q, et al. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747-2761.
44. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, et al. (2006) A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 125: 987-1001.
45. Ura S, Nishina H, Gotoh Y, Katada T, (2007) Activation of the c-Jun N-terminal kinase pathway by MST1 is essential and sufficient for the induction of chromatin condensation during apoptosis. Mol Cell Biol 27: 5514-5522.
46. Alfthan K, Heiska L, Gronholm M, Renkema GH, Carpen O, (2004) Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 279: 18559-18566.
47. Kissil JL, Johnson KC, Eckman MS, Jacks T, (2002) Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 277: 10394-10399.
48. Tang X, Jang SW, Wang X, Liu Z, Bahr SM, et al. (2007) Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol 9: 1199-1207.
49. Madhunapantula SV, Robertson GP, (2009) The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 22: 400-419.
50. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, et al. (1997) Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 7 (Suppl 2): S35-42.
51. Brunckhorst MK, Wang H, Lu R, Yu Q, (2010) Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res 70: 7283-7293.